CCM
ALLO icon

Coldstream Capital Management’s Allogene Therapeutics ALLO Stock Holding History

Coldstream Capital Management’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-205
Closed -$300 – 1191
2025
Q1 		$300 Buy
+205
New +$386 ﹤0.01% 3444

Other funds holding ALLO

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Coldstream Capital Management's ALLO Position: Q2 2025 in Review

Coldstream Capital Management sold out of Allogene Therapeutics (ALLO) in Q2 2025, closing a stake of 205 shares — an estimated $300 sold.

Coldstream Capital Management first reported a position in ALLO in Q1 2025 and held it in 1 quarter. The position peaked at $300 in Q1 2025. 158 funds tracked by Wall St. Rank hold ALLO as of Q2 2025.

  • Coldstream Capital Management reported no remaining Allogene Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Coldstream Capital Management sold 205 Allogene Therapeutics shares in Q2 2025, an estimated $300.
  • Coldstream Capital Management first reported a position in Allogene Therapeutics in Q1 2025 and held it in 1 quarter.
  • Coldstream Capital Management's Allogene Therapeutics position peaked at $300 in Q1 2025.
  • 158 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2025.

Based on Coldstream Capital Management's 13F filing for Q2 2025, filed 12 Aug 2025.